Fenbendazole Dosing
Oct.3, 2023 – FENBENDAZOLE and CANCER – at least 12 Anti-Cancer mechanisms of action. Not approved by FDA. Cheap. Safe. Kills aggressive cancers. Why no Clinical Trials? Nine research papers reviewed.
Recent Studies
- (2024 Apr, Rodrigues et al) – Repurposing mebendazole against triple-negative breast cancer CNS metastasis
- (2024 Feb, Eid et al) – Investigating the Promising Anticancer Activity of Cetuximab and Fenbendazole Combination as Dual CBS and VEGFR-2 Inhibitors and Endowed with Apoptotic Potential
- (2024 Feb, Park et al) – The microtubule cytoskeleton: A validated target for the development of 2-Aryl-1H-benzo[d]imidazole derivatives as potential anticancer agents
- (2024 Jan, Matsuo et al) – Parbendazole as a promising drug for inducing differentiation of acute myeloid leukemia cells with various subtypes
- (2023, Dec, Iragavarapu-Charyulu et al) – A novel treatment to enhance survival for end stage triple negative breast cancer using repurposed veterinary anthelmintics combined with gut‑supporting/immune enhancing molecules
- (2023 Nov, Aliabadi et al) – In vitro and in vivo anticancer activity of mebendazole in colon cancer: a promising drug repositioning
- (2023 Nov, Jung et al) – Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma
- (2023 Sep, Garg et al) – Network pharmacology and molecular docking study-based approach to explore mechanism of benzimidazole-based anthelmintics for the treatment of lung cancer
- (2023 Jun, Mukherjee et al) – Ketogenic diet as a metabolic vehicle for enhancing the therapeutic efficacy of mebendazole and devimistat in preclinical pediatric glioma
- (2023 Feb, Lee et al) – Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine
Mebendazole
Here are the references for this dosing schedule:
- For Maximum dose of 4g/day being safe, that’s from a Phase 2 Clinical Trial for Gastrointestinal Cancer: (2021 Mansoori et al)
- (2021 Chai et al) – summarizes the various studies that have looked at Mebendazole in Cancer and the doses used.
- 500mg-1500mg/day (Phase 1 Clinical Trial, pediatric brain tumors)
- 200mg/day (2011 Dobrosotskaya et al) (adrenocortical ca)
- 200mg/day (2014 Nygren et al) (colon ca lung and LN mets)
- 100mg/day (Clinical Trial, UK)
- So far, several studies in the literature have used 200mg/day with some success, however given that it is safe to go up to 4g/day, when we’re dealing with aggressive mRNA Induced Turbo Cancers, 200mg/day is probably not sufficient.
- Why Mebendazole over Albendazole (2021 Chai et al):
- “However, because of the toxicity of albendazole, for example, neutropenia due to myelosuppression, if high doses are used for a prolonged time, mebendazole is currently more popularly used than albendazole in anti-cancer clinical trials.”
Mebendazole is FDA approved. It’s expensive. Check out “Fenbendazole vs Mebendazole for Cancer“.
(adapted from https://www.onedaymd.com/2024/07/ivermectin-articles-and-protocols-for.html)
